A cancer drug in-licensed by German biotech major BioNTech (Nasdaq: BNTX) from China-based Biotheus could be a good one, if mid-stage results shared at the European Society for Medical Oncology (ESMO) are anything to go by.
PM8002/BNT327 is a bispecific antibody targeting PD-L1 and VEGF-A. BioNTech agreed to pay up to $1 billion to develop the drug in an agreement with Biotheus signed in November last year.
Results have been presented at ESMO from a single-arm Phase II safety and efficacy study of PM8002/BNT327 in combination with chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze